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Abstract 
 
Introduction Colon cancer is defined as the third most common cancer leading to death in the 
developed world. Several research are ongoing, in order to improve treatments.  Recent 
studies shows interest in the transcriptional regulation of the fusion genes VTI1A-TCF7L2, 
which shows a correlation with colon cancer. This study investigates the promoter region of 
the fusion gene.  
Methods LS174T cells were cultivated and seeded in a 96 well plates and plasmids were 
constructed containing the promoter of VTI1A and CDX2 or SP1. The cells were thereby 
harvested and lysed. The activity of luciferase and β-galactosidase were then measured by a 
luminometer. 
Discussion and conclusion The results showed that the SP1 gene does not have an effect 
alone with VTI1A. CDX2 together with VTI1A showed a higher value compared to VTI1A 
alone. CDX2 and SP1 combined, gives the highest value of the constructed plasmids.   
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This project is devised by Jannie Jørgensen, Pia Ringh Bohi, Redaa Al-Makdisi 
Razeeghi, as a 5th semester project in molecular biology on the Bachelor of Natural Science 
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The aim of the project was to investigate the properties of the promoter region VTI1A-
TCF7L2 fusion protein. This was done by certain steps and experiments in the laboratory. 
The project group would like to thank our supervisor Johanne Davidsen, for constructive and 
excellent guidance during the whole period. Furthermore, we would like to thank her for her 
contributions to the design and execution of the experiment. 
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Reading guide  
This report is organized, initially with the theory section, subdivided into two categories. First 
describing the normal conditions, followed by the abnormal terms. 
Hereafter, the materials and methods used for the experiment are described, followed by the 
results and the subsequent processing of the results from the experiment. Calculation 
examples are given. These sections will together lead to a discussion section followed by a 
conclusion. 
                   For an overview, the entire name of the biological agent is mentioned and after 
that only the abbreviations are used, example: Adenomatous polyposis coli (APC). 
                   Finally, we refer to tables and calculations in the appendix. This section is 
placed at the end of the project, with numbers. 
Methods 
In this project, we used several methods to work with our problem statement. The main study 
was literature surveys, where we used scientific articles, including reviews- and original 
articles, to respond to the theory sections about the fusion gene, the SNARE-proteins and the 
signaling pathways. 
Furthermore, we used textbooks to respond to the theory sections about colon, cancer, cancer 
cells and oncogenes. Protocols were additionally used for the experimental parts of the 
project. 
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Introduction 
 
Colon cancer was identified as a frequent cause of cancer-related deaths in Denmark. It is a 
type of cancer developed in colon, because of uncontrolled cell changes. The human body 
contains many cells that have different functions to perform, live and divide in homeostasis. 
Cells can start dividing uncontrolled and unrestricted without signals, resulting in tumor 
development. 
                  Several studies are investigating colon cancer, showing that oncogene mutations 
play a crucial role in the development of colon cancer. Previous studies show a significant 
correlation between colon cancer, oncogenes and pathways, such as Adenomatous Polyposis 
Coli (APC), β-catenin and Wingless-Type 1 (Wnt-signalling). A study presented by Polakis, 
2007, identified that mutations in the APC, is a main cause of Familial Adenomatous 
Polyposis Coli (FAP), which is a predisposition of colon cancer (Paul Polakis, 2000). APC is 
involved in destabilization of the β-catenin protein, where Wnt functions as stabilization 
signal. The APC effect on β-catenin results in mutations in β-catenin, where it no longer can 
be regulated. This process is a part of the Wnt-signalling pathway. Other studies show a 
fusion of proteins on chromosome 10 in colon cancer tumors. Bass et al, showed that the Vps-
ten-interacting-1a (VTI1A) gene and the Transcription factor 7-like 2 (TCF7L2) gene are 
fused together in 3% of spontaneous colon cancer tumors. Furthermore, the TCF7L2 gene 
encodes a T-cell factor (TCF4), which is a target of the Wnt-signalling pathway. Changes and 
rearrangements in the Wnt-signalling pathway is thought to have a role in colon cancer 
development. 
                    
In this project we will investigate the properties of the promoter region of the VTI1A-
TCF7L2 fusion protein. This will first be studied by using our background knowledge about 
the fusion genes VTI1A and TCF7L2, to then construct an experiment where we will 
investigate the transcriptional regulation of the VTI1A-TCF7L2 fusion genes using cultured 
cells and transfections. 
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Delimitation  
As in other fields, this study is unlimited. The project is therefore limited, thus the sections 
included, focus on the transcriptional regulation of the promoter region of the VTI1A-TCF7L2 
fusion gene.  
The project include theory sections about colon and their stem cells, because of 
their importance in the colon crypts and transcription factors, such as TCF4, CDX2 and SP1. 
These are included because of their role in the experimental section. Theory about Wnt-
signalling pathway, APC and β-catenin are also included because of their crucial roles in 
colon cancer progression. Finally the two fusion genes are described in proportion to the 
problem statement.  
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1. Theory   
1.1 The colon 
This section deals with the function and structure of the colon. 
The colon is one of three parts in the large intestine, where the cecum and the rectum are the 
two others. The large intestine starts at the end of ileum and ends at the anus. The colon is the 
second step in the large intestine and its main function is to absorb the vitamins and nutrients, 
metabolized earlier in the digestion system (Widmaier et al., 2011). It differs from the small 
intestine by the size, as it has a larger diameter and a thinner wall. The region of the colon is 
further divided into four parts as following: the ascending-, the transverse-, the descending- 
and the sigmoid colon (Martini et al.,  2015)(Figure 1). 
 
 
 
 
Figure 1 shows a picture of the colon, including the ascending-, the transverse-, the descending- and the sigmoid 
colon. The rectum is also shown (modified from (Mindandbodyflow.com, 2014)) 
 
The wall of the colon consists of four layers of tissues. The first layer, which is the inner 
layer, is called the mucosa. The mucosa is a combination of three layers: Lamina propria, 
muscularis mucosa and the epithelium. 
The layer below the mucosa is called submucosa. This layer functions as a connective tissue 
layer. The third layer is called muscularis externa, which is the muscular tissue of the 
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intestinal wall. The contraction of the muscles in this layer ensures the impact for moving the 
contents of the intestine. 
The last layer of the colon wall is called the serosa. The serosa is a thin layer of another 
connective tissue, which surrounds the outer surface of the intestine wall (Martini et al., 
2015). The figure below (figure 2) shows a diagrammatic view of the colon wall, containing 
the different layers. 
 
 
Figure 2 shows a diagrammatic view of the colon wall (Modified from Martini et al., 2015) 
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1.2 Stemcell, proliferation and differentiation 
 
 
Figure 3 shows proliferation of the cells in crypts (modified from Carulli et al., 2014). For further elaboration, see 
the text. 
 
Figure 3 (Carulli et al., 2014) shows a crypt of Lieberkühn in the colon (hereafter just 
called crypts). The boxes illustrate the compartmental model of homeostasis. Displacement in 
the equilibrium of homeostasis could lead to tumorigenesis. Both the stem cell and the semi-
differentiated cell have the ability to renew itself, and both types of cells can die and thus the 
differentiation will not proceed (Johnston et al., 2007). The compartmental model divide the 
crypts into three compartments. One for the stem cells, one for the semi-differentiated cells 
and one for the fully differentiated cells. The amount of each type of cells are determined by 
the rate of renewal, death, differentiation and removal, and small alterations in one of the 
possible fates of the cells, will lead to either massive growth or decay of cells. This 
displacement of equilibrium of the crypt is suggested to lead to tumorigenesis. 
The green cells in the bottom of the crypt are the stem cells. A stem cell is a primitive 
cell type, with the ability to differentiate into a more specialized cell type, here indicated as 
purple cells; which again can differentiate into a fully differentiated cell, the orange cells. 
This differentiation will happen as the cell migrates up the crypt. From a stem cell, it will 
evolve into colonocytes, enteroendocrine cells and Goblet cells; ending at the luminal 
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surface, where the cell will eventually undergo apoptosis, shed into the lumen, and ultimately 
be transported out of the body with the feces. 
The colonocyte is an epithelial cell and the enteroendocrine cells produce and secrete 
peptide hormones, which influence the motility of the bowel movement. 
The function of the Goblet cells is to produce and secrete mucin which, along with a 
minor amount of other related glycoproteins, works as a lubricant in the transport of the feces 
and as a protective layer on the epithelial (Geneser, 2011). Figure 4 shows a microscopy 
picture of the intestinal crypts, where the tissue has been colored in order to detect mucin 
levels. 
  
Figure 4 Alcian blue colour for the detection of mucin in colon (Photo from private library, 2012). 
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1.3 Wnt-signaling pathway 
The canonical Wnt-signaling pathway (also known as the wnt/β-catenin pathway) is 
an intracellular pathway, where the wnt ligand stimulates a cell, which ultimately leads to 
gene transcription. 
The wnt signaling pathways (wnt) are a group of signal transduction pathways made of 
proteins, that pass signals from outside of the cell to receptors on the inside of the cell. In 
humans there are 19 different wnt genes ( Katoh, 2007), that code for different proteins, yet 
they all bind to the same receptors, thereby all triggering the same pathway. Wnt-1, -3 and -8 
activate the wnt/β-catenin pathway (Behrens & Lustig, 2004), which we will be focusing on. 
Wnt signals control multiple aspects of development, including the proliferation, fate 
specification, polarity, and migration of cells. In addition, over activation of wnt signaling by 
mutation is a major factor in oncogenesis in the human colon and other tissues (Behrens & 
Lustig, 2004; Logan & Nusse, 2004; P Polakis, 2012). 
Wnt binds to two separate receptors simultaneously. One receptor is the Frizzled (Fz) 
receptor, which is a 7-transmembrane polypeptide (Behrens & Lustig, 2004). There are 10 
known Fz-receptors, and they work by binding ligands to the amino terminal, located on the 
extracellular side of the polypeptide. 
The other receptor that wnt binds to, is either LRP5 or LRP6. LRP means LDL-receptor 
related protein and wnt needs one of them for binding and starting the signaling inside the 
cell. The co-receptor LRP is essential for signal transmission (Behrens & Lustig, 2004; 
Logan & Nusse, 2004). 
In a normal cell, where wnt is not bound (figure 5), a complex is formed inside the 
cell to destroy the β-catenin protein. This complex consists of two proteins: Axin and APC, 
plus the enzymes glycogen synthase kinase-3β (GSK-3β) and casein kinase-1α (CK-1α). This 
complex binds to β-catenin and the kinases phosphorylates the protein. Now β-TrCP (a 
negative regulator of the pathway)(Marikawa & Elinson, 1998)can bind and add ubiquitin 
groups, which acts as a marker for degradation by proteasomes (Behrens & Lustig, 2004; 
Logan & Nusse, 2004). 
As shown on figure 5, Groucho also plays a part in the absence of a wnt-signal. This protein 
binds to TCF and repress gene transcription (Logan & Nusse, 2004). 
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Figure 5 is an illustration of a cell without Wnt-signaling (Eisenmann, 2005) 
 
When wnt is present in the extracellular fluid, as shown in figure 6, and binds to Fz 
and Low-Density Lipoprotein Receptor-related Protein (LRP), the intracellular protein 
Dishevelled (Dsh) can bind to the carboxyl group of the transmembrane Fz protein and 
recruit Axin from the degradation complex. When the complex is not formed, β-catenin 
accumulates in the cell and enters the nucleus. APC is also involved in this transport (Behrens 
& Lustig, 2004). Inside the nucleus, the β-catenin acts as a transcriptional activator by 
binding to T-cell factor/Lymphoid Enhancer-binding Factor (TCF/LEF), which is a family of 
transcription factors. Normally TCF/LEF is repressed, but by binding of β-catenin, it changes, 
and the gene is transcribed. 
The TCF/LEF family have four members: TCF1, TCF4, LEF1 and TCF3. TCF1 and 
TCF4 are especially good at regulating transcription (Hoverter et al., 2014). 
 
 
Figure 6 is an illustration of a cell with Wnt-signaling (Eisenmann, 2005) 
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1.4 Transcription factors 
A transcription factor with influence on the maturing of colon cells is TCF4. 
 
Figure 7 TCF4 expression in normal cells on the left of the crypt, and TCF4 mutant cells on the right (Angus-Hill, 
Elbert, Hidalgo, & Capecchi, 2011) 
 
As shown on figure 7, in the healthy epithelia of the colon, a low level of TCF4 in the bottom 
of the crypt will favor high proliferation and a high level in the top will promote 
differentiation of the cells (Angus-Hill et al., 2011). The TCF4 protein plays an important 
role in the development of the intestine in the embryo. Laboratory experiments with mice 
pups, which are lacking the TCF7L2 gene that codes for TCF4 shows that the mice are not 
viable; they will die within 24h. Furthermore, the intestines of the mice are without crypts 
and the tissue is necrotic, indicating that the TCF4 protein is important in the development of 
healthy intestine (Angus-Hill et al., 2011). 
Other important transcription factors in the development and maintenance of the 
intestine are Caudal type Homeobox 2 (CDX2) and Special Protein 1 (SP1). CDX2 is a 
nucleoprotein coded by the CDX2 gene. Its major function is to participate in the regulation 
and differentiation of the cells in the intestines (Guo, Funakoshi, Lee, Kong, & Lynch, 2010), 
and it works by activating genes, responsible for maturing of the epithelia in the intestine, 
gallbladder and pancreas. CDX2 is essential for the expression of the glycoprotein mucin in 
the colon (Vyberg, 2011). 
SP1 is a transcription factor with a known influence on the regulation of the cell 
growth, survival of the cell and cell cycle regulation. The SP1 protein binds to promoters 
with GC-rich sequences. The SP1 protein is composed of 785 amino acids, of which 164 
amino acids are serine or threonine residues (Beishline & Azizkhan-Clifford, 2015). These 
16/47 
 
residues are able to be phosphorylated, which alter the function of the transcription factor. 
The phosphorylation can lead to an inhibiting or exchanging effect on the function of SP1 
(Beishline & Azizkhan-Clifford, 2015). 
Coskun, Boyd, Olsen, & Troelsen, 2010 found in their study, using transfection with PEI on 
colon cells, which the presence of SP1 alone does not alter the cell activity more than two-
fold and that cells with the CDX2 plasmid alone give a four-fold activity. The cells with both 
transcription factors present, will experience a 10-fold activity, strongly indicating that CDX2 
and SP1 emphasize each other (Shimakura, Terada, Shimada, Katsura, & Inui, 2006). 
 
1.5 The genes VTI1A and TCF7L2 
1.5.1 VTI1A 
The VTI1A-gene is coding for a so-called v-SNARE protein, whereas the TCF7L2 encodes 
the transcription factor TCF4. 
  When proteins are transported from the ER, through the Golgi body and out of the 
cell, they are folded and carried out through the plasma membrane in vesicles (Devlin, 2002). 
SNARE-proteins are a family of proteins that are required for the transport of these vesicle, 
and they are often divided into subcategories: V-SNAREs (vesicular SNAREs) and t-
SNAREs (target SNAREs) (Alberts, Bray, Johnson, Lewis, Raff, 1998; Lehninger, 2013). 
In order for a fusion between two membranes can occur, the SNARE of the carrier vesicle 
binds with the target SNARE. The binding results in a structural change, where helices of the 
two SNAREs intertwine, and pull the two membranes closer to each other, thus the fusion of 
membranes can occur (Lehninger, 2013).  This is illustrated on figure 8. 
 
 
Figure 8 Function of the v- and t-SNAREs 
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Research by Walter et al., 2014, showed that cells lacking the VTI1A gene have both 
smaller and fewer vesicles, indicating VTI1A´s involvement in the formation of the vesicles. 
  
1.5.2 TCF7L2 
As already mentioned, TCF7L2, codes for TCF4. The TCF4 protein is also seen as a 
necessity for the maintenance of the epithelial stem-cell compartment in the lower part of the 
crypts in the intestine (“Genetics home reference,” 2004). 
  
Up until now we have described how colon cells are regulated, when it comes to signaling 
and gene transcription. 
A dysregulation of genes can sometimes cause cancer. The next section deals with the 
progression of cancer 
  
18/47 
 
2.Cancer 
Cancer is a comprehensive term used to define diseases in different tissues and organs 
in the human body caused by mutations. Tissues and the different cell types in the body are 
always in a state, where they replenish, divide and differentiate in order to control and 
replace the cells that die. 
This process and different signaling pathways are main factors, to keep and maintain 
the functions of the different organs in our body (Griffiths et al., 2012). Like other 
mutations, mutations in genes in these processes lead to uncontrolled cell proliferation and 
tissue disruption. The uncontrolled cell proliferation forms a tumor, which is the main 
characteristic in cancer progression. According to (Borup, 2010), cancer cells are defined 
with six characteristics, which differ from normal cells. 
                 The 1st characteristic is the contact between the cells and mitogens. Mitogens 
are chemical substances that give cells signals to start divide. This part is missed in cancer 
cells because of mutations, and the cells will start divide without stimuli. 
                 The 2nd characteristic is the control of cell proliferation. In normal cells, the 
process where cells divide can be controlled and slowed down if the cell density becomes 
tight or if there is DNA damages. This part is missing and uncontrolled in cancer cells 
because of the mutation and the inhibition of stimuli reactions. 
                 The 3rd characteristic is the cell’s dependence of survival factors and the 
apoptosis. Apoptosis is a programmed cell death. This part is deactivated in cancer cells, 
because of mutations in the signal pathways. This results in survival of cancer cells without 
stimuli. 
                 The 4th characteristic is the cell’s limitation to divide. This process is driven 
by telomeres, which controls the limitation of cell division by shorten them. This part is also 
missing in cancer cells, where the gene of the enzyme telomerase is activated, resulting in 
maintenance of the telomere ends. 
                 The 5th characteristic is the cell’s ability to get rid of waste. This ability 
requires that the cells are near a blood supply, and the tumor cells can therefore induce 
development of new blood vessels, angiogenesis. 
                 The 6th and last characteristic is the cell’s last phase metastasis, where the cells 
change their conditions. When cancer cells progresses to a tumor, the tumor can send cells 
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in the blood/lymph stream, resulting in dissipating and surviving in other tissues than the 
origin region.     
 
Summary of the characteristics of cancer cells, modified from Borup 2011: 
1.      Mitogens 
2.      Cell proliferation 
3.      Apoptosis 
4.      Telomeres 
5.      Angiogenesis 
6.      Metastasis 
2.1 Colon cancer and APC 
In the DNA replication system, the cells replicate and correct themselves, when 
needed by the cells replication systems. If there are mutations in the replication process, the 
genes will be mutated, and then they are referred to as oncogenes (Griffiths et al., 2012). 
           Human cancers, including colon cancer, are caused by mutations in genes. 
These lead to cell proliferation, which at some point results in a tumor. The oncogenes 
encode a complex of proteins, which only is activated by a certain type of signals and can act 
both as positive or negative regulators. Mutation in both types of oncogenes can lead to 
unregulated proliferation of cells, where the activity of the mutated protein is uncoupled from 
its regularly signaling pathway  (Griffiths et al., 2012). When it comes to colon cancer, the 
gene mutation most often found occurs in the APC-gene. APC is a regulatory protein, and has 
a main role in tumor progression. When APC is mutated, the β-catenin constantly induce cell 
division leading to unwanted gene transcription. Furthermore APC affects the chromosome 
separation in mitosis. Absence of APC will therefore lead to chromosomal instability. The 
above mentioned will together increase the rate of tumor progression, where the mutated 
APC will induce hyperproliferation of the enterocytes, resulting in polyp formation in the 
colon (Borup, 2010). 
  
In a tumor cell, the β-catenin degradation complex may have a mutation, which 
leads to accumulation of β-catenin. This means that a gene can be transcribed, without having 
received a wnt-signal. In colon cancer it is very common to see mutations in the 3’-region of 
the gene encoding TCF4 (Logan & Nusse, 2004; P Polakis, 2012). 
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Wnt-signaling is thereby a very important factor in the development of colon tumors. 
APC is a tumor suppressor, a part of the β-catenin degradation complex and can down-
regulate β-catenin (Behrens & Lustig, 2004; P Polakis, 2012). A mutation in this protein 
could lead to uninhibited cell proliferation. Its function in the transfer of β-catenin into the 
cell nucleus could thus lead to unwanted TCF transcription, without wnt-signaling 
(Schneikert, 2007). 
 
2.2 The fusion of VTI1A-TCF7L2 
The fusion of the two neighboring genes on chromosome 10, VTI1A and TCF7L2 has 
been detected in 3% of primary colorectal cancer tumors (Bass et al., 2011). The fusion is 
caused by an approximately 540 kb deletion of the last five exons of VTI1A, and the first 
three exons of TCF7L2 (Figure 9). This deletion results in a truncated fusion gene coding for 
a fusion protein, lacking the β-catenin-binding domain (Nome et al., 2014). 
The normal promoter region of TCF7L2 coding for TCF4 is gone, which means that once the 
transcription of VTI1A is initiated, the transcription of TCF7L2 will also be initiated; and 
only as a consequent of transcription of VTI1A (Nome et al., 2014). 
 
Figure 9 A section of chromosome 10, where the VTI1A and TCF7L2 genes are scaled up. The box illustrate the 
deletion of exons in the fusion gene 
 
 
The purpose of the study is to investigate the promoter region of the VTI1A-TCF7L2 fusion 
gene. This is based on an experiment, which will be described in the following section.  
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3. Methods and materials 
The main aim of the experiment was to analyze the activity of the fusion genes 
in colon cancer cells (LS174T). Plasmids with the fusion genes were thereby constructed. 
Furthermore a reporter assay was done, where the promoter was inserted into the plasmids 
that express luciferase and β-galactosidase. These were transfected into the cells and the 
activity was measured by a luminometer, according to the protocol for Dual Light system, 
See appendix 4. 
 
 
Figure 10 Shows a pGL4.10 plasmid map, where the restriction enzyme HindIII, have a restriction site, just before 
the luciferase gene. VTI1A is then inserted. (Biotech, 2015) 
 
 
 
 
3.1 Cell culture 
For the transfection, we split the cells twice a week. This was done by 
resuspending the cells into new media, so they can freshly grow in a new environment. 
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The process consists of 5 steps, where the first was to suck out the old media from the cells. 
The second step was to wash the cells with sodium citrate, approximately 3 times, and then 
remove it. Trypsin is a protein-digest enzyme, and is added next to release the cells from the 
flask, followed by incubation for no more than five minutes. Growth medium is added, and 
since it inactivates trypsin, we do not remove this. 10μl of the suspension was lastly put into a 
Bürker Türk counting chamber, for counting the number of cells, because we needed 3 
million cells for the transfection. We counted the cells in at least two chambers, and used the 
mean value to calculate how many mL were transferred. 
  
3.2   Transfection 
We transfect the cells with a mixture of cells and PEI – the latter binds the plasmids 
together. 
For the wells we are going to use for the transfection, we made one big mix of medium and 
cells, in total 25 mL (we made the mix for one extra). We had 4 replicas of each plasmid 
combinations, which are divided into 24 wells and we wanted 100.000 of cells in each well. 1 
mL of medium and cells were transferred into each well. 
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Figure 11 Shows a fourfold replicate of each plasmid combination. pGL4.10 in first row coloured in nude. 
pGL4.10-VTI1A in second row coloured in orange, pGL4.10-VTI1A + CDX2 in third row coloured in blue, 
pGL4.10-VTI1A + SP-1 in fourth row coloured in purple and the untransfected cells in sixth row coloured in 
grey 
For the transfection, we constructed 6 combinations from 7 plasmids. The 
following plasmids were used for the transfection and were made beforehand: 
 
Plasmid Properties  
CMV-SP1 Plasmid containing SP1 
CMV-LacZ Measurement of the β-galactosidase, because it expresses β-
galactosidase and is thereby used for the determination 
efficiency of the transfection.   
pCDNA 3.1+ An empty CMV vector. 
 
pGl4.10 VTI1A Luciferase promoter plasmid containing VTI1A 
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pHIV.dTomato CDX2 Plasmid containing CDX2 
pGL4.10 Luciferase promoter plasmid without our VTI1A gene 
SK+ An empty plasmid, added to have equal amount of DNA in 
each well. 
Table 1 shows the different plasmids: CMV-SP1,CMV-LacZ, pCDNA 3.1+, pGl4.10 VTI1A, pHIV.dTomato CDX2, 
pGL4.10 and SK+, together with their properties. 
 
For the construction of the plasmids, the concentrations, see appendix 1, were used in 
order to make dilutions for the combinations used for transfection,  
Following equation was used for making the dilutions  C1*V1 = C2 * V2 : See appendix 2 for 
the calculations. The concentrations were then measured by Nanodrop. See appendix 3 for the 
measurements. 
 
 
 
To each well (2-5) pGL4.10 or pGL4.10-VTI1A was added, as a luciferase promoter plasmid 
and CMV-LacZ plasmid was also added to each well. Furthermore, either CDX2, SP1 or 
cDNA3.1+ was added to the wells.  
To each well SK+ was then added to have a total DNA concentration of 300 ng. 150mM of 
NaCl was also added to adjust the volume of the transfection mix, ending up with a total 
volume of 100μl. 
Each replicate had a transfection mix of 100μl DNA, mixed with 100 μl of 
Polyethyleneimine-25 (PEI-25). After the addition of PEI-25, the mix was incubated for 1 
hour. 
 
 
The plate was then spun for 5 minutes, 1200 rpm, followed by incubation overnight. After the 
incubation the media was removed from the cells and new media was added. 
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3.3   Luciferase and β-galactosidase measurement 
Two days after the transfection, the cells were harvested. Buffer solutions for 
the measurement were made according to protocol, see appendix 4. The cells were washed 
with 300μl Phosphate-Buffered Saline (PBS) after the media was removed. The PBS was 
then removed and 130μl of lysis buffer with DTT, was added to the cells, followed by gently 
shaking for 5 minutes, then stored on ice until the analysis. 
                   10μl of the cell extract was transferred to the 96-well microplate, where we 
only used 24 of the wells, according to protocol, see appendix 4. The activity of both 
luciferase and β-galactosidase was then measured by a luminometer, but in order to get a 
clear reading of the β-galactosidase, we waited for 1 hour before this measuring. Otherwise 
the emitted light from the luciferase could interfere with our results. 
  
Step 2 and 3 was repeated, resulting in two sets of results to discuss further. 
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4. Results 
 
  Plasmid constructions luciferase β-galactosidase 
       
 1 pGL4.10 205,75 394517 
 2 pGL4.10-VTI1A 54993,75 479642 
1. Experiment 3 pGL4.10-VTI1A + CDX2 77603 326376 
 4 pGL4.10-VTI1A+ SP-1 45933,5 435826 
 5 pGL4.10-VTI1A + CDX2 + 
SP-1 
136289,75 429701 
 
  Plasmid constructions luciferase β-galactosidase 
       
 1 pGL4.10 21,5 7771,75 
 2 pGL4.10-VTI1A 775,5 7832,5 
2. Experiment 3 pGL4.10-VTI1A + CDX2 829,5 4415,5 
 4 pGL4.10-VTI1A + SP-1 957,5 9936,5 
 5 pGL4.10-VTI1A + CDX2 + 
SP-1 
2432,25 7948,25 
Table 2 shows the average of the raw data from the luciferase and β-galactosidase measurements, from both 
experiment 1 and 2. See appendix 5 for the data. 
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5. Subsequent processing of results 
This section describes the processing of the results from the transfection, both experiments 
included. There are six calculation steps, followed by graphs. 
In the experiment, we also had a construction of untransfected cells (well 6). This was done 
to see if there were any impurities that would interfere with our results. The measurement 
was very low and does not influence on our results, and are therefore not included in this 
processing. 
 
  
1.  We divide the luciferase-value with the β-galactosidase value, because we want the 
normalized value of luciferase. The β-galactosidase activity shows how well our plasmids 
were transfected. 
An example follows from pGL4.10-VTI1A from our first transfection: 
luciferase/β-galactosidase → 52303/408774 = 0,12795 
The method is used for all the calculations (1-5), See appendix 6  
 
 
2.  We calculate the average of the luciferase/β-galactosidase of pGL4.10-VTI1A without 
transcription factors, and use this number in later calculations, because we want to see the 
difference between the plasmid with and without transcription factors. 
The average is = 0,11507 
  
3. The third step is to calculate the relative luciferase. This step is done, by dividing the 
(luciferase/β-galactosidase) for each transfection with the average of the luciferase/β-
galactosidase for pGL4.10-VTI1A, see appendix 7 for the calculations: 
The relative luciferase → 0,12795/0,11507 = 1,11 
 
 
4. The fourth step was to calculate the average of the relative luciferase by taking the 
average of the relative luciferase pr. plasmid construction and compare it to the pure plasmid. 
We adjusted the average of pGL4.10-VTI1A to 1, so we can more easily compare our results, 
see appendix 8 for the average calculations.  
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5. Next we calculated the standard deviation to see if there is a significant difference 
between the replicas. This is done by using the tool for statistics in Excel. 
We also find the probability value (p-value)of the below mentioned combinations. 
● VTI1A vs. CDX2 
● VTI1A vs SP-1 
● VTI1A vs CDX2 + SP-1 
  
This is done to see if there actually is a difference between our findings. 
By using a confidence interval of 95%, we can conclude that any p-value above 5% does not 
show any significant difference between the compared units, and vice versa. 
We compare the above-mentioned compounds against each other, and the transfections from 
both experiments against each other, See appendix 9, for the p-values.  
 
6. Bar charts are then constructed, using Excel, to show the difference between the 
plasmid constructions and the standard deviations are included, See appendix 10 for the 
values put into the bar charts.  
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5.1 Statistics 
This section, shows the two bar charts achieved after the 6 subsequent steps above. 
 
 
 
Figure 12 shows a graph containing the plasmid combinations; pGL4.10, pGL4.10-VTI1A, pGL4.10-VTI1A + 
CDX2, pGL4.10-VTI1A + SP-1 and pGL4.10-VTI1A + CDX2 + SP-1 from the first and second experiment. 
 
 
As we expected, the first pillar is non-existent, because we do not have any VTI1A 
here, and therefore no luciferase activity. Of the other pillars we see that overexpressing only 
the SP1 gene, does not have much of an effect (pillar 4), compared with pillar number 2, 
which is only the VTI1A gene. The 3rd  pillar shows our plasmid with the CDX2 transcription 
factor, and as we expected, the value is higher than the 2nd pillar. 
The 5th pillar shows that the two transcription factors combined, give the highest amount of 
luciferase-activity. 
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6. Discussion 
The aim of this project was to investigate the transcriptional regulation of the promoter region 
of VTI1A-TCF7L2. According to our theory, see section 1.5. This region is the same as in the 
VTI1A gene alone, which is why we constructed a plasmid containing only the promoter 
region of the VTI1A gene. 
There may be a difference between how many plasmids each of the cells have 
obtained at the transfection. The CDX2 plasmid, combined with pHIV-dTomato, which 
contains a fluorescence protein. This can be detected as a red color in an electron microscope 
(“Add gene,” 2014), and this would have been a way to investigate if the plasmid was 
efficiently transfected into the cells. However, the procedure we followed is a very common 
way of transfecting cells. It’s a well known procedure, and the validity is reason enough  not 
to implement this control in our experiment. We use PEI, which makes the plasmids clump 
together, and this ensures the transfection of the given plasmids into the cell. 
                   As shown in our results, the SP1 factor does not have much of an effect by 
itself, whereas CDX2 shows almost double the value. Combined, these factors have almost 
tripled in value, which tells us that one upregulates the other, see section 4.1. 
The results from this experiment are similar to a study made by Coskun et al.,2014 showing a 
two-fold increase in SP1 and a four-fold increase in CDX2. The study also showed that when 
the two factors were combined, they got a ten-fold increase in promoter activity. 
Furthermore, SP1 was found to be dose-dependent, meaning a higher luciferase was achieved 
concurrently with an increase in SP1 amounts. Coskun proposed a theory showing, SP1 that 
affects CDX2 to produce a higher value, when the two factors were combined. 
SP1 has multiple sites that can be phosphorylated. The effect of SP1 depends on whether a 
residue causing enhancement or inhibition is phosphorylated (Beishline & Azizkhan-Clifford, 
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2015). This makes it hard to conclude on our results alone, what kind of effect SP1 has in our 
experiment, but we can see that it has a crucial role in affecting CDX2.  
Moreover, this is confirmed with the study of Mehmet Coskun et al., 2014, where SP1 is 
found to upregulate CDX2. CDX2 is an autoregulator, which binds to its own promoter, and 
thereby upregulates its own transcription. It is a factor required for normal colon cell 
development, which is why we expected an effect. 
VTI1A encodes a protein that assists in communication between the endoplasmic 
reticulum and the Golgi body, by transferring vesicles. A study made by Walter et al., 2014, 
found that a mutation in this gene results in fewer and smaller vesicles, but the protein was 
still functional. A mutation in this gene alone is therefore less interesting when investigating 
the fusion gene, and we will focus mostly on the consequences of the mutation of the second 
part of the fusion gene VTI1A-TCF7L2.  
When it comes to the fusion of VTI1A-TCF7L2 there is only one allele to consider, 
since the cell line used in this study, is lacking a sister chromatid. This means, that a normal 
gene cannot overtake the function of the abnormal gene. In cancer, this is an undesirable 
feature, as opposed to this experiment, where it is no longer an important factor to focus on. It 
is possible that an APC mutation is the cause of this loss of chromatid. When a cell undergoes 
mitosis, the chromatin is divided before the cell splits into two, and it is found that APC has a 
role in this process. A mutation in APC will cause chromosomal instability, as described in  
Borup, 2010. 
If CDX2 is overexpressed, the promoter region of the VTI1A gene will activate, 
leading to expression of the fusion gene. Study made by Hiroshi Yamamoto, Yun-Qing Bai, 
2003 showed that CDX2 is essential to the MUC2 gene. This gene expresses the glycoprotein 
mucin, found in the differentiated cells at the top of the colon crypts. This means, that if the 
mutation is present in these types of cells, the fusion gene will be expressed, but the result is 
until now unknown.  
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A protein must be folded correctly to be able to function properly. If the tertiary and 
quaternary structure is abnormal, a loss or alteration of the protein is expected. When it 
comes to the fusion protein, we know that the expressed protein is truncated, but we do not 
know what the function of it is. It is possible that there are no consequences, if the truncated 
protein can mimic the properties of TCF4. 
A single point mutation of DNA, can generate a completely new amino acid 
sequence, changing the function of the protein. In the fusion gene, the mutation is  a deletion 
of 540-kb (Bass et al., 2011; Nome et al., 2014), which can lead to other considerable 
consequences. The truncated fusion protein lacks a β-catenin binding site, which means that 
the wnt-signaling pathway has no effect anymore. β-catenin is a very important factor, 
because it is the binding of this protein, that activates the gene transcription. Without a 
binding site, proper transcription cannot occur, and a protein like TCF4 will not be expressed. 
Colon cells without TCF4 stimulation will therefore not surpass to the differentiating phase, 
but will stay in proliferation. Abnormal proliferation of cells is one of the characteristics of 
cancer, see section 1.6. It is furthermore known, that β-catenin activates the TCF/LEF family, 
which TCF4 is a member of. When β-catenin accumulates and enters the nucleus, it binds to 
one of the members. 
In approximately 80% of all colon cancer cases, a mutation in APC is found (Behrens 
& Lustig, 2004). APC regulates cell proliferation and is an important part of wnt-signaling, 
by its interaction with β-catenin. When TCF4 is down-regulated, the cells will continue to 
divide and possibly now in the top of the crypt instead. Normally, proliferation occur in the 
bottom of the crypt and by migration of the cells up towards the intestinal lumen, they will 
start differentiating, as TCF4 increases. 
The transcription of the fusion gene is activated by the presence of CDX2, which is found in 
the middle and the top of the crypt (Guo et al., 2010). This means that the location for cell 
proliferation changes.  
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The human organism has a defense against gene mutations. A mismatch-repair system 
controls that unnatural gene sequences are spliced out, before the gene is expressed. 
However, this system can also be mutated and lead to cancer (Anthony J. F. Griffiths, Susan 
R. Wessler, Sean B. Carroll, 2012b). A study of oncology, describes that mutation in both 
APC and the mismatch-repair system does not occur simultaneously, and we therefore 
assume, that the system is intact in our cells. This leads to the thought that if the repair system 
does not splice out the fusion gene, it may be because it does not seem unnatural to the repair 
system. This could indicate, that the mutation has been in the organism all along, and 
possibly inherited.  
7. Conclusion  
In this project we investigated the properties of the promoter region  VTI1A-TCF7L2 
fusion protein.  This was done by constructing an experiment, where we investigated the 
transcriptional regulation of the VTI1A-TCF7L2 fusion genes using cultured cells and 
transfections. 
The results from the experiments showed the highest upregulation in the plasmid containing 
CDX2 and SP1 together with the promoter region of VTI1A. This means that the two 
transcription factors together have an effect on the promoter region of VTI1A, where they 
activate the transcriptional regulation. We found this to correlate with previous studies.  
We can therefore conclude that CDX2 and SP1 have an influence on the fusion gene, 
which under certain circumstances causes colon cancer. 
We are dealing with a spontaneous cancer, but since the discovery of the fusion gene is new, 
the possibility of inheritance cannot be fully excluded. 
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Appendix 
Appendix 1 
Plasmids Concentration ng/μl 
CMV-SP1 1000  
CMC-LacZ 1520  
pCDNA 3.1+ 2180,4  
pGl4.10 VTI1A 1214  
pHIV.dTomato CDX2 1822  
pGL4.10 238  
SK+ 2641,2  
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Appendix 2 
 
 pGL4.10        
DNA in μl 
pGL4.10-
VTI1A 
CMV-
LacZ CDX2 SP-1 
cDNA 
3+ pSK+ total 
150mM 
NaCl 
pGL4.10  5,71 11,90   10,05 15,05 42,72 57,28 
pGL4.10-VTI1A 6,45 11,90   10,05 15,05 43,46 56,54 
pGL4.10-VTI1A + CDX2 6,45 11,90 11,17  10,05 11,47 51,05 48,95 
pGL4.10-VTI1A + SP-1 6,45 11,90  14,49  15,05 47,90 52,10 
pGL4.10-VTI1A + CDX2 + 
SP-1 6,45 11,90 11,17 14,49  11,47 55,49 44,51 
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Appendix 3  
 
Plasmids Concentration ng/μl 
CMV-SP1 10,5 
CMC-LacZ 55,8 
pCDNA 3.1+ 17,9 
pGl4.10 VTI1A 9,3 
pHIV.dTomato CDX2 8,4 
pGL4.10 19,9 
SK+ 24,9 
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Appendix 4 
Luciferase/galactosidase measurement on Glomax 
luminometer - Protocol for Dual Light system 
  
Harvesting cells: 
Before harvesting, make the lysis buffer by adding DTT 1M (0.5mM final conc.) to the lysis 
solution (0.5µL DTT/mL Lysis buffer).    
  
1.                       Wash each well with 1xPBS (200-300µl). Remove all PBS from wells. 
2.                       Add 130µl Lysis solution to each well. Place the plate on shaker or shake by 
hand for approx. 5 min. 
3.                       Place the plates in ice until you are ready to analyze. For later analysis, the 
plates are stored at -20°C or - 80°C. 
4.                       Transfer 10µl of cell extract from each sample to a 96 well plate.  
  
  
Measuring luciferase: 
Before measuring, add Galacton-Plus to buffer B.   
  
1.                       Turn on the Glomax machine, and open the program on the computer. Press 
‘open saved protocol’ and choose “BufA-BufB” (saved in ‘glomax protocols’). 
2.                       Put buffer A and B on the machine. Prime both injectors (injector 1 with 
buffer A and injector 2 with buffer B) into the waste container. Place the injectors back in the 
injector holder. 
3.                       Put the 96 well plate in the machine. If you do not have a complete 96 well 
plate, choose which wells you are measuring on in the options menu. Check that injection 
volume for injector 1 is set at 25 µl, injector 2 at 100 µl, also in the options menu. 
4.                       Press start. When all the wells have been measured, save your data by 
pressing ‘save a copy as’ in the menu tab. 
5.   Reverse purge both injectors. If you are done measuring, press ‘flush’ and follow the 
steps listed. 
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Measuring galactosidase 
1.  Incubate your samples 30-60 min (from the measurement of the first sample) at room 
temperature. 
2.  Open the protocol “Dual Light Accelerater II”  (saved in ‘glomax protocols’). 
3.  Put Accelerator II on the machine and prime injector 1 into the waste container. Place the 
injector back into the injector holder. 
4. Put the 96 well plate in the machine – again choose which wells are to be measured in the 
options menu. Check that the injector volume for injector 1 is set at 100 µl. 
5.Press start. Save data by pressing ‘save a copy as’ in the menu tab. 
6. Reverse purge injector 1. Press ‘flush’, choose both injectors, and follow the steps listed. 
  
Calculation of buffers for measurements and priming: 
24 wells: 
Lysis solution: 130x24 = 3120        à 3.5mL + 1.75µL DTT (1M) 
Buffer B: 100x24 + 1500 = 3900    à 4 mL + 40µL Galacton-Plus 
Buffer A: 25x24 + 1500 = 2100      à 2,2mL 
Accelerator: 100x24 +1500 = 3900 à 4mL 
96 wells: 
Lysis solution: 130x96 = 12480      à13mL + 6.5µL DTT(1M) 
Buffer B: 100x96 + 1500 = 11100     à 11.5mL + 115µL Galacton-Plus 
Buffer A: 25x96 + 1500 = 3900       à 4mL 
Accelerator: 100x96 +1500 = 11100à 11.5mL 
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Appendix 9 
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Appendix 10  
 
1st experiment upregulation Std. 
pGL4.10  0,00 0,00 
pGL4.10-VTI1A 1,00 0,09 
pGL4.10-VTI1A + CDX2 2,06 0,23 
pGL4.10-VTI1A + SP-1 0,92 0,12 
pGL4.10-VTI1A + CDX2 + 
SP-1 2,76 0,30 
   
   
2nd experiment upregulation Std. 
pGL4.10 0,03 0,01 
pGL4.10-VTI1A 1,00 0,19 
pGL4.10-VTI1A + CDX2 1,97 0,49 
pGL4.10-VTI1A + SP-1 0,98 0,20 
pGL4.10-VTI1A + CDX2 + 
SP-1 3,17 0,38 
 
 
 
